Correlative analysis of overall survival with clinical characteristics in 127 patients with mantle cell lymphoma: a mult
- PDF / 1,443,936 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 28 Downloads / 170 Views
ORIGINAL ARTICLE
Correlative analysis of overall survival with clinical characteristics in 127 patients with mantle cell lymphoma: a multi‑institutional cohort in Taiwan Yu‑Hung Wang1,2 · Shan‑Chi Yu3 · Bor‑Sheng Ko2,4 · Yi‑Tsung Yang1,5 · Ming Yao2 · Jih‑Luh Tang2,4 · Tai‑Chung Huang2 Received: 9 March 2020 / Revised: 26 April 2020 / Accepted: 29 May 2020 © Japanese Society of Hematology 2020
Abstract Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma often with extranodal involvement at diagnosis, and yet how this feature correlates with survival awaits elucidation. To address this issue, a correlative analysis between clinical features of 127 MCL patients and their overall survival (OS) was conducted. In this cohort, the median age at MCL diagnosis was 62 years and 81% were males. Eighty-four percent of patients were Ann Arbor stage 4, and 15% were blastoid variants. In patients with gastrointestinal MCL, approximately 40% had gastric involvement. In treatment, CHOP-based induction chemotherapy was given to 61.1% of patients. One-third of patients undertook autologous stem cell transplant (SCT), and 4.7% had allogeneic SCT. The median OS was 82 months and well-stratified in MIPI risk groups. In the multivariate analysis for OS, blastoid variants and gastric involvement were both independent risk factors whereas auto-SCT had a protective effect. Overall, this study corroborated with the current understandings and international therapeutic standards for MCL. Auto-SCT associated with a better OS while allo-SCT remained an option for blastoid variants and those who failed AutoSCT. Interestingly, patients with gastric involvement tended to have worse survival, a finding that spawns more studies to investigate the mechanism. Keywords Mantle cell lymphoma · Gastric involvement · Stem cell transplantation · Multi-institutional · Taiwan
Introduction Electronic supplementary material The online version of this article (https://doi.org/10.1007/s12185-020-02903-z) contains supplementary material, which is available to authorized users. * Tai‑Chung Huang [email protected] 1
Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan
2
Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, No. 7, Chung‑Shan S. Rd., Taipei City 10002, Taiwan
3
Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan
4
Department of Hematological Oncology, National Taiwan University Cancer Center, Taipei, Taiwan
5
Division of Hematology‑Oncology, Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan
Mantle-cell lymphoma (MCL) is a rare but aggressive B-cell non-Hodgkin lymphoma [1, 2]. At diagnosis, MCL is mostly with the advanced stage and extranodal involvement [3, 4]. The clinical course, however, might be variable even in patients belonging to different risk groups [5]. Chemoimmunotherapy followed by high-dose chemotherapy with autologous stem cell transpl
Data Loading...
